These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 34721716)

  • 1. Patient-Specific Dosimetry in Radioligand Therapy (RLT) for Metastatic Prostate Cancer Using
    Mahmoudi E; Pirayesh E; Deevband MR; Amoui M; Rad MG; Ghorbani M
    Nucl Med Mol Imaging; 2021 Oct; 55(5):237-244. PubMed ID: 34721716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dosimetry for (177)Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer.
    Delker A; Fendler WP; Kratochwil C; Brunegraf A; Gosewisch A; Gildehaus FJ; Tritschler S; Stief CG; Kopka K; Haberkorn U; Bartenstein P; Böning G
    Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):42-51. PubMed ID: 26318602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lacrimal Glands May Represent Organs at Risk for Radionuclide Therapy of Prostate Cancer with [(177)Lu]DKFZ-PSMA-617.
    Hohberg M; Eschner W; Schmidt M; Dietlein M; Kobe C; Fischer T; Drzezga A; Wild M
    Mol Imaging Biol; 2016 Jun; 18(3):437-45. PubMed ID: 26920354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-therapeutic dosimetry of 177Lu-DKFZ-PSMA-617 in the treatment of patients with metastatic castration-resistant prostate cancer.
    Yadav MP; Ballal S; Tripathi M; Damle NA; Sahoo RK; Seth A; Bal C
    Nucl Med Commun; 2017 Jan; 38(1):91-98. PubMed ID: 27782913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Organ and tumor dosimetry including method simplification for [
    Karimzadeh A; Schatz L; Sauer M; Apostolova I; Buchert R; Klutmann S; Lehnert W
    EJNMMI Phys; 2024 Jul; 11(1):63. PubMed ID: 39017988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Accuracy in Calculation of Absorbed Dose to the Kidneys Following Radioligand Therapy with
    Mahmoudi E; Pirayesh E; Deevband MR; Amoui M; Rad MG
    Indian J Nucl Med; 2022; 37(2):121-125. PubMed ID: 35982806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Examining Absorbed Doses of Indigenously Developed
    Kamaldeep ; Wanage G; Sahu SK; Maletha P; Adnan A; Suman S; Basu S; Das T; Banerjee S
    Cancer Biother Radiopharm; 2021 Apr; 36(3):292-304. PubMed ID: 32379495
    [No Abstract]   [Full Text] [Related]  

  • 8. Personalized dosimetry assessment of [
    Kazemi-Jahromi M; Yazdani E; Karamzade-Ziarati N; Asadi M; Sadeghi M; Geramifar P
    Int J Radiat Biol; 2024 Sep; ():1-9. PubMed ID: 39302840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer.
    Kabasakal L; AbuQbeitah M; Aygün A; Yeyin N; Ocak M; Demirci E; Toklu T
    Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):1976-83. PubMed ID: 26227531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dosimetry and safety of
    Paganelli G; Sarnelli A; Severi S; Sansovini M; Belli ML; Monti M; Foca F; Celli M; Nicolini S; Tardelli E; Marini I; Matteucci F; Giganti M; Di Iorio V; De Giorgi U
    Eur J Nucl Med Mol Imaging; 2020 Dec; 47(13):3008-3017. PubMed ID: 32430583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy.
    Baum RP; Kulkarni HR; Schuchardt C; Singh A; Wirtz M; Wiessalla S; Schottelius M; Mueller D; Klette I; Wester HJ
    J Nucl Med; 2016 Jul; 57(7):1006-13. PubMed ID: 26795286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiation Dosimetry for
    Okamoto S; Thieme A; Allmann J; D'Alessandria C; Maurer T; Retz M; Tauber R; Heck MM; Wester HJ; Tamaki N; Fendler WP; Herrmann K; Pfob CH; Scheidhauer K; Schwaiger M; Ziegler S; Eiber M
    J Nucl Med; 2017 Mar; 58(3):445-450. PubMed ID: 27660138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of different methods for post-therapeutic dosimetry in [
    Rosar F; Schön N; Bohnenberger H; Bartholomä M; Stemler T; Maus S; Khreish F; Ezziddin S; Schaefer-Schuler A
    EJNMMI Phys; 2021 May; 8(1):40. PubMed ID: 33950333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dosimetry of
    Violet J; Jackson P; Ferdinandus J; Sandhu S; Akhurst T; Iravani A; Kong G; Kumar AR; Thang SP; Eu P; Scalzo M; Murphy D; Williams S; Hicks RJ; Hofman MS
    J Nucl Med; 2019 Apr; 60(4):517-523. PubMed ID: 30291192
    [No Abstract]   [Full Text] [Related]  

  • 15. [44Sc]Sc-PSMA-617 Biodistribution and Dosimetry in Patients With Metastatic Castration-Resistant Prostate Carcinoma.
    Khawar A; Eppard E; Sinnes JP; Roesch F; Ahmadzadehfar H; Kürpig S; Meisenheimer M; Gaertner FC; Essler M; Bundschuh RA
    Clin Nucl Med; 2018 May; 43(5):323-330. PubMed ID: 29485430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiomics Analysis for
    Kelk E; Ruuge P; Rohtla K; Poksi A; Kairemo K
    Life (Basel); 2021 Feb; 11(2):. PubMed ID: 33671761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of Normal Organ Absorbed Doses for [177Lu]Lu-PSMA-617 Using [44Sc]Sc-PSMA-617 Pharmacokinetics in Patients With Metastatic Castration Resistant Prostate Carcinoma.
    Khawar A; Eppard E; Sinnes JP; Roesch F; Ahmadzadehfar H; Kürpig S; Meisenheimer M; Gaertner FC; Essler M; Bundschuh RA
    Clin Nucl Med; 2018 Jul; 43(7):486-491. PubMed ID: 29688951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-in-human dosimetry of gastrin-releasing peptide receptor antagonist [
    Kurth J; Krause BJ; Schwarzenböck SM; Bergner C; Hakenberg OW; Heuschkel M
    Eur J Nucl Med Mol Imaging; 2020 Jan; 47(1):123-135. PubMed ID: 31482426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intra-therapeutic dosimetry of [
    Peters SMB; Privé BM; de Bakker M; de Lange F; Jentzen W; Eek A; Muselaers CHJ; Mehra N; Witjes JA; Gotthardt M; Nagarajah J; Konijnenberg MW
    Eur J Nucl Med Mol Imaging; 2022 Jan; 49(2):460-469. PubMed ID: 34218300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient-specific image-based bone marrow dosimetry in Lu-177-[DOTA
    Gosewisch A; Delker A; Tattenberg S; Ilhan H; Todica A; Brosch J; Vomacka L; Brunegraf A; Gildehaus FJ; Ziegler S; Bartenstein P; Böning G
    EJNMMI Res; 2018 Aug; 8(1):76. PubMed ID: 30076556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.